Podcasts about eversana

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company committed to advancing precision medicine, for a conversation on this space and a new frontier of biomarkers. Quagliata discusses Thermo Fisher's ongoing collaboration with EVERSANA, pharmaphorum's parent company, and that collaboration's investigation of the impact of utilising electronic health record (EHR) data in haematological cancers to support the company's value proposition for ultra-fast next generation sequencing (NGS) with oncomine myeloid solutions. That included a presentation at Frontiers Health 2024, in Berlin, in the deep dive, ‘Overcoming data linkage barriers with tokenization technology: RWE on the use of targeted therapy and its impact on survival in blood malignancies' – presented alongside Dr Pierantonio Russo, Corporate Chief Medical Officer at EVERSANA.

Welcome to this month's P4A Let's Talk Rare podcast episode by Partners4Acess. Today, Georgie and Owen are joined by Leonard Mazur, CEO of Citius Pharmaceuticals, to discuss their innovative therapy, Lymphir, for cutaneous T-cell lymphoma (CTCL). Leonard shares his journey with Citius, from its founding in 2013 to the recent resubmission of Lymphirto the FDA, and discusses the drug's potential to alleviate severe itching for the 21,000 annual CTCL patients in the U.S. The conversation also covers Citius's commercialisation plans and ongoing trials exploring Lymphir's use for other conditions. Join Georgie, Leonard, and co-host Owen for an insightful discussion on how Citius is committed to improving patient quality of life through groundbreaking treatments! Leonard explains how Citius acquired Lymphir in 2021, a drug facing regulatory challenges that they've addressed for FDA resubmission, with potential approval expected. They discuss Lymphir's benefits, especially for CTCL patients, including its potential to relieve severe itching and outline the company's commercialisation plans with Eversana. Leonard emphasises the team's extensive expertise as vital to navigating the regulatory process. They also explore Lymphir's off-label potential for other cancers, with ongoing trials at major universities. The conversation closes on the rewarding impact of pharmaceutical work on patient lives, underscoring Citius's commitment to addressing unmet medical needs through innovative treatments. Leonard Mazur Bio: Leonard Mazur is a seasoned entrepreneur and executive with over five decades of experience in the pharmaceutical industry. He is known for his skill in founding and growing multiple healthcare companies. Currently CEO of Citius Pharmaceuticals, Leonard previously co-founded Leonard-Meron Biosciences and Akrimax Pharmaceuticals. He also led Triax Pharmaceuticals as COO, specialising in dermatology, and successfully sold his dermatological company, Genesis Pharmaceuticals, to Pierre Fabre in 2003. His extensive background spans roles in sales, marketing, and business development at Medicis, ICN, Knoll Pharma, and Cooper Labs. Born in Germany, Mazur holds an MBA from Temple University, where he also earned his undergraduate degree. He is an Ellis Island Medal of Honor recipient. Episode Resources: Leonard Mazur on LinkedIn Citius Pharmaceuticals Website Owen Bryant on LinkedIn Georgina Rack on LinkedIn Partners4Access Website  P4A Let's Talk Rare podcast on Apple Podcasts

— On a cold and cozy December night in 2018, Jim Kaveney thinks he is dying. He is a husband, a father, a business owner, an athlete, and innovator. He is also an Afib patient facing massive cardiac trauma. In his memoir, Unlimited Heart: How To Transform Your Pain Into Purpose, Jim Kaveney recounts his dance with death and the events of his life leading up to this fateful, health-defining moment and the shifts in business perspective and priorities that followed. Unlimited Heart takes readers on a three-part, forty-year journey. It traverses the tight budgets of an eleven-member household to the financial burdens strapped to a dream to the sale of a multi-million-dollar startup. It is a raw portrayal of a boy who grapples with his own demons in the midst of his dreams and a man who turns those dreams into a clear, entrepreneurial vision—a vision that is threatened by medicine, technology, and surgeries.  Kaveney's entrepreneurial and cardiac journey cannot be separated. Where his heart was weak, his mind became strong. When his mind was weak, his heart was strong. His battle between his metaphorical and physical heart and mind is what inspired him to write Unlimited Heart and to launch a business with the namesake. Turning his pain in life to a greater purpose, Unlimited Heart helps people with cardiac issues be different and better patients. Valeria interviews Jim Kaveney — He is the author of  “Unlimited Heart: How To Transform Your Pain Into Purpose.” Jim Kaveney is all heart. In 2012 Jim founded Alkemy Partners (a Life Sciences Learning and Performance company that was ranked by Inc5000 in 2019 and 2020 before achieving acquisition in 2020 by EVERSANA™) and he is currently the founder of Unlimited Heart Health &  Wellness —a collaborative organization of health care professionals accelerating cardiac innovation. After years of balancing entrepreneurial ambitions with his own growing cardiac issues, Jim Kaveney, M.S. has turned his pain into a purpose to become an expert in navigating the burgeoning worlds of digital therapeutics, global startup initiatives, and the mindset training required to tackle the pillars of a holistic work-health-faith-family-life balance. Growing up as the youngest of nine in Erie, Pennsylvania, he sought understanding and solace in forces greater than himself, a quest that has influenced his personal and professional journey. Through his story, he hopes to empower others to find strength and resilience in the face of health challenges, while continuing to innovate and advocate for better patient care solutions. To learn more about Jim Kaveney and his work, please visit: https://unlimitedheartbook.com/ and connect with him on https://www.linkedin.com/in/jameskaveney/

Ashley Cox is a strategic leader in the Life Sciences sector and female founder, who has recently founded Caledonia Life Sciences. This is a consultancy specialising in corporate strategy and business development for early-stage biotech & pharmaceutical companies. With a solid background in European business development, she has held senior roles at prominent firms like EVERSANA & SmartAnalyst. Ashley is also a dedicated advocate for women in the healthcare industry, contributing over 6 years to the Healthcare Businesswomen's Association, including roles as Regional Chair of Northern Europe & President of the London Chapter. Hear how to make the jump to starting your own company, what more we can do to encourage women in STEM, what we can learn from great & terrible leaders, the value of Cultural Intelligence (CQ), and her hopes & fears for AI (Artificial Intelligence). Connect with Shirley at ShirleyKavanagh.com and on LinkedIn, and Ashley on LinkedIn

The ESMO congress always disseminates the latest results of cancer research, a vibrant gathering and sharing of the latest data, communicating the next promising steps in oncological scientific development, ever seeking to address unmet patient needs. So it was that pharmaphorum Web Editor Nicole Raleigh found a quiet spot onsite in Barcelona this year to catch with experts from EVERSANA and discuss their takeaways from the 2024 conference. Tune in to hear more from: Ann Marie Robertson, Chief Commercial Officer, EVP, EVERSANA COMPLETE Oncology, EVERSANA; Barry Vucsko, Senior Vice President, Client Services and Business Development Leader, EVERSANA INTOUCH; Vanitha Sankaran, VP, Medical Strategy, EVERSANA INTOUCH; and Gurdip Daffu, PhD, VP, Medical Strategy (Oncology), EVERSANA INTOUCH. From the unique to the specifics of antibody-drug conjugates (ADCs) and advancements in women's cancers, to the proliferation of AI and where it's all going, and from diagnostics to excitement and hope at what's on the cusp and what's yet to come – the sense of bated breath potential is palpable.

In today's episode of Elevate Your Career, Nicole is joined by Eduard de Vries Sands, Chief Information Officer at Eversana, an independent provider of global commercial services to the life science industry.During the conversation, Nicole and Eduard discuss the nuances of leadership and career advancement, emphasizing the importance of continuous learning and broadening one's knowledge base. You'll discover the value of staying informed about financial matters and how being well-versed in these areas can elevate one's position in the corporate world. Get a glimpse into the delicate balance between professional responsibilities and personal life. Eduard shares personal anecdotes about integrating work and family time, demonstrating how to maintain productivity while enjoying meaningful moments with loved ones.Don't miss another episode of the Elevate Your Career podcast. Leave a review and subscribe today!What You Will Learn In This Show:The benefits of expanding your expertise beyond your immediate role to include business and financial literacy.The importance of making deliberate career decisions and the impact of those choices on your personal and professional life.The powerful influence of role models in shaping career aspirations and leadership styles.How specific books can provide practical insights into leading and transforming organizations.The enriching experiences of traveling and immersing yourself in different cultures.And so much more...Resources:Eduard's LinkedInEversana

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce the completion of the initial phase of an assessment conducted by EVERSANA® Life Science Services, LLC on the U.S. market opportunity for Tonmya. Tonmya represents a potential groundbreaking first-line therapy for fibromyalgia management, positioning itself as a non-opioid, centrally-acting alternative in a market dominated by opioids. Lederman highlighted the concerning dominance of opioids in the fibromyalgia prescription market, despite well-documented risks of dependency. Tonmya aims to address this gap by offering a safer, non-addictive option for fibromyalgia patients. EVERSANA's primary market research indicates promising interest from physicians, with a median interest rating of 4.0 on a 5-point scale and an intended use of Tonmya in 40% of fibromyalgia patients upon approval. The analysis also noted that approximately 50% of fibromyalgia patients in the U.S. are on Medicare. The Inflation Reduction Act, effective in 2025, will cap out-of-pocket prescription drug costs for Medicare patients, which could improve access to Tonmya if approved. With the submission of the New Drug Application (NDA) for Tonmya slated for the second half of the year, Tonix Pharmaceuticals anticipates an FDA decision on approval by 2025. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #TonixPharmaceuticals, #FibromyalgiaTreatment, #NewDrugApplication, #TunMyo, #NonOpiateAnalgesic, #ChronicPain, #MarketAssessment, #SanaLifeSciences, #PhaseThreeStudies, #Cyclobenzaprine, #FibromyalgiaAwareness, #BiotechNews, #DrugDevelopment, #PainManagement, #HealthcareInnovation, #Medicare, #InflationReductionAct, #PrescriptionDrugCosts, #PharmaceuticalResearch, #FDAApproval #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

On this special Live broadcast of the @Alloutcoach Podcast I welcomed back Dr. Pierantonio Russo, Chief Medical Officer at EVERSANA, cardiac and heart transplant surgeon trained at Mayo Clinic, academic medical school lecturer, expert in health economics and population medicine, bioinformatics, Machine Learning, and digital medicine to the show to share the highlights from his recent state of the art presentation of the "Hospital of the Future" in Rome, Italy. He is a renowned physician executive and speaker who has a healthcare experience from all its angles as a chief clinician in cardiac surgery, health insurance decision-maker, health system leader and administrator, and therefore shares his specific cases of med tech innovations already underway as well as the critical success factors including personalizing healthcare delivery using remote patient monitoring or applying social determinants of health data. 0:00 Episode Introduction 1:48 Dr. Pierantonio Russo - Journey of a Healthcare Career from all of its Angles 6:14 Health Innovations Already Underway w/ Strongest Impact 13:44 Why Certain Health Systems are More Successful in Adopting Innovation 15:28 When will Health Tech Innovations Go Mainstream to the Community 17:36 Specific Outcomes of AI / ML on Patient Outcomes 22:45 Role of Convenience in Health Innovation - Quadruple Aim 26:57 Impact of Med Tech on the Art of Medicine or Decision-Making 29:39 What are the economic real-world benefits of Med Tech? 32:18 AI/ML can improve Social Determinants of Care and Value-Based Care 35:17 Final Message: Critical Steps to Consider Which Technology to Implement in Medicine

Welcome to the PRmoment Podcast.Welcome to our November review of PR Pitches and mergers & acquisitions in the UK PR scene with Andrew Bloch.He is the lead consultant - PR, Social, Content and Influencer at the new business consultancy firm AAR and a partner at PCB Partners, where he advises on buying and selling marketing services agencies.Andrew was also a co-founder at PR agency Frank PR, where he is still a non-executive director at Frank PR.Before we start, we've got some huuuuge news - The PRmoment Awards 2024 are now - OPEN!There are some exciting changes this year; we've tweaked the categories, refined the entry form and launched a regional champions scheme with no additional entry fee to reach the work across the UK.Do check out the PRmoment Awards microsite.Also, thanks so much to the PRmoment Podcast sponsors the PRCA.Finally, thanks to PRmoment's data and insight partners, Meltwater, for supporting this podcast.2 mins Andrew on how this year's pitch golden quarter is going!Andrew's current outlook for public relations:“Things won't really pick up pace until the second quarter next year.”“Great companies do well regardless of the economy, and it's the ones that aren't as well run, that aren't as strong, that suffer when the economy wobbles.”“I think we will see an uplift overall in (PR) industry in spending this year.”“Because we're always on…we are more protective of when we do get some shut off time.”6 mins  How does Andrew look back on the pitching year of 2023?“Not a boom year…but healthy.”“Tech's had a tough year, but coming out of it now…you're already seeing that come back. Which is great.”9 mins Andrew and Ben reflect on the sad news that Science Magic, previously The London Communications Store, has gone into voluntary receivership.“This was a sizable firm of over 100 people.”“You can look at lots of agencies and quite clearly see they are overstaffed for the level of fee income they've got.“Now you have a lot of specialists within an agency…who aren't necessarily direct revenue drivers.”“PR firms have a higher cost base now than they ever have.”11 mins This month's PR new business news:Tin Man wins Mars Pet Care (Royal Canin) and Yeo Valley.Sunny Side Up wins Majestic WineJohn Doe wins the Pernod Ricard wine portfolio and Sports Direct.Duet London wins INSHURFrank wins Lounge.tv and Not On The High StreetRed wins Toshiba TVThree Sixty wins Wizz AirThe Romans wins The Gym Group, Formula E and Tony's ChocolonelyHatch wins 365H&K wins Philips Domestic AppliancesPHA wins Alith PayLittle Red Rooster wins Hush Puppies26 mins November's PR M&A News:Life Sciences firm Eversana have acquired digital health consultancy Healthware GroupFreuds buys creative art agency Lawless StudiosUS private equity firm EagleTree Capital buys MMGY GlobalHavas buys Indian consumer firm PR Pundit.Splendid buys DIY Creative.

In the latest episode of the Alloutcoach Podcast I spoke with Dr. Pierantonio Russo, (Corporate Chief Medical Officer @Eversana), a cardiac and heart transplant surgeon, former Chief of Cardiac Surgery and Pediatric Cardiac Surgery at a various top academic hospitals across the U.S. with expertise in machine learning, data analytics, health economics and population medicine with leadership roles at large national health plans such as Independence Blue Cross and Harvard Pilgrim Health. In this conversation he shares his enthusiasm for the potential of computation and technology to advance medicine and addresses critical topics of health equity, electronic medical records, and quality of care. Dr. Russo discusses numerous specific case studies from state of the art examples and publications from other innovators in medicine as well as from his career to explain how he has applied his experience as a clinical, administrative, and academic leader in medicine to impact large populations of patients using advanced data analytics, Machine Learning, AI and medical informatics. 3:42 What are some of the most memorable moments in your career as a cardiac transplant surgeon? 5:21 How did his experience as a cardiac surgeon spark his interest in studying the impact of computation and machine learning on advancing medicine? 6:59 How do you think health payers can partner with providers to help make better clinical decisions? 13:52 How are health providers who work at health plans responding to unprecedented growth in the volume of data to better identify and analyze patients? 16:31 Examples of predictive ML models in healthcare directly affecting and improving quality of care 22:06 Are there differences in access to genetic testing in the US vs other countries? 22:57 How can advanced ML models help identify genetic mutations earlier at the RNA level? 26:20 What is the focus of your current work at EVERSANA? 29:03 What type of data is required to ensure access to trials or treatments, adherence and maintenance of care? 33:03 How can patients hold on to their own patient records so they can expect to receive the same high quality of care as they move from one provider or health system to the next? 35:25 Dr Russo: Take caution when you interpret medical information across various social and other media outlets. 36:53 How do you hope to improve the explainability of ML/AI applications in medicine through your education and enthusiasm for their potential?

In this episode of Life Science Success, my guest is Rohit Sood  EVP, COMPLETE Commercialization at EVERSANA.  He is a life sciences strategy and operations executive with a passion for developing teams and solving business challenges. Track record of driving topline business growth while identifying significant operational efficiencies in PE-backed, startup, and publicly-listed organizations.   Rohit Sood and Don Davis discuss challenges faced by organizations during the commercialization phase Eversana helps smaller biotechs evaluate the process of commercialization and provides support through it Good leadership inspires Rohit, and he values transparency and clarity in decision-making Short-term thinking and not listening to advisors concerns Rohit Traveling and food excite Rohit

In this podcast, Sharlene Jenner, vice president of engagement strategy at Abelson Taylor and professor of AI and personalization for digital marketers at Southern Methodist University, leads a panel of five industry leaders in a roundtable discussion. The conversation delves into the practicalities of current AI applications and confronts the ethical and regulatory issues related to the technology. The panelists also explore the direct consequences and prospective implications of AI, providing listeners with a snapshot of the present and an outlook on the transformative potential of emerging technologies in the pharmaceutical marketing sphere. The panel consists of: Faruk Capan, chief innovation officer, EVERSANA, and CEO, EVERSANA INTOUCH; Anurag Banerjee, CEO and founder, Quilt.AI; Jeff Headd, vice president, commercial data science, The Janssen Pharmaceutical Companies of Johnson & Johnson; and Stephen Onikoro, senior principal, head of strategy, PharmaForceIQ. Sponsored by: ZS https://www.zs.com/

In episode 72 of The Gradient Podcast, Daniel Bashir speaks to Brigham Hyde.Brigham is Co-Founder and CEO of Atropos Health. Prior to Atropos, he served as President of Data and Analytics at Eversana, a life sciences commercialization service provider. He led the investment in Concert AI in the oncology real-world data space at Symphony AI. Brigham has also held research faculty positions at Tufts University and the MIT Media Lab.Have suggestions for future podcast guests (or other feedback)? Let us know here or reach us at editor@thegradient.pubSubscribe to The Gradient Podcast:  Apple Podcasts  | Spotify | Pocket Casts | RSSFollow The Gradient on TwitterOutline:* (00:00) Intro* (01:55) Brigham's background* (06:00) Current challenges in healthcare* (12:33) Interpretablity and delivering positive patient outcomes* (17:10) How Atropos surfaces relevant data for patient interventions, on personalized observational research studies* (22:10) Quality and quantity of data for patient interventions* (27:25) Challenges and opportunities for generative AI in healthcare* (35:17) Database augmentation for generative models* (36:25) Future work for Atropos* (39:15) Future directions for AI + healthcare* (40:56) OutroLinks:* Atropos Health homepage* Brigham's Twitter and LinkedIn Get full access to The Gradient at thegradientpub.substack.com/subscribe

What can I say, Ashley Cox and I have grownup in the Pharmaceutical industry together. Since we first met over 19 years ago, and I hired her into the industry (I have a knack for identifying top talent!), it has been an absolute joy to see her career evolve and go from strength to strength.Ashley now heads up the European region for Eversana Consulting as Senior Principal, and is the UK President for the Healthcare Businesswoman's Association.In this fun chat we reminisce, give advice to our younger selves, and explore all areas of Ash's leadership career.  The highs, the lows, and everything in between.It was so much fun to record this interview, and it is an absolute joy to bring it to you, jam-packed full of insights and tips.A few teasers:Navigating redundancy and curve-balls at workGiving yourself permission to be authentically you, and then finding the right environment to thriveThe importance of getting comfortable with discomfortThe value of having a coach, and building a robust support crew around youHow to support the next generation of talent in this virtual working worldExpanding your career horizons through networking and volunteeringThe power of stepping back as a leaderGetting comfortable with the fact not everyone will like youPlus so much more…As always, I would love to hear what jumps out to you from this powerful conversation!JennAs always, I love to hear what jumped out to you from this conversation.  DM me on LinkedIn here: https://www.linkedin.com/in/jennfenwick/ Feel free to EMAIL me @ jenn@jennfenwick.comWant to work together?  Let's find a time to chat: https://meetings-eu1.hubspot.com/jenn-fenwick/virtual-coffee-call

How are real world evidences generated, collected and used for health economics assessment? What are some biostatistics related roled within life science consulting? How will the life science consulting industry potentially evolve in the future? Tim Disher is here to answer all these questions for you! Dr. Tim Disher obtained his PhD degree in Nursing from Dalhousie University working on economic evaluation of neonatal health technologies. He is now a registered nurse and serves as senior director of Biostatistics at Eversana. His expertise includes developing and critiquing models from both statistical and clinical point of view. He is also interested in the latest tech developments and believes they can eventually assist and change the life science consultancy workflow. Let's dive into this episode to see what Tim shared with us Please visit our website https://biostatisticspodcast.github.io/ for the latest updates and transcripts of the published episodes. If you have any comments, feedback or suggestions, feel free to email us via biostatisticspodcast@gmail.com or DM us on Twitter @BiostatsPodcast Powered by Firstory Hosting

Jack gets Eversana CDO Scott Snyder's JPM observations on digital health. Marc comments on Eisai's pricing transparency. And Lecia discusses efforts to strengthen oversight of “gain-of-function” research. We close with the recent controversy surrounding a MrBeast video. Follow us on twitter: @MMMnews www.mmm-online.com

In this episode of AI For Pharma Growth, Dr Andree Bates is joined by Mike Ryan, Vice President of Eversana.   They discuss the future of pharma and the impact of recent advancements in healthcare. The industry is facing a unique moment, with technology opening up new possibilities for medical interventions and a greater focus on patient outcomes. The combination of artificial intelligence, big data, and shifting customer expectations are driving major changes in healthcare and pharmaceuticals. The industry must be prepared to embrace these changes and take bold steps to succeed in this new landscape.   In this episode you will learn: Why healthcare is undergoing rapid change How technological advancements drive new opportunities in medical interventions Why customer expectations drive transformation in healthcare and pharmaceuticals How the pharmaceutical industry must embrace change to succeed in this new landscape.   Click to connect with Dr. Andree Bates for more information in this episode: https://eularis.com/   Click for more information about Eversana:  https://www.eversana.com/   AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business.    This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.   As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses  her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.    This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more.   Resources:  Dr. Andree Bates LinkedIn | Facebook | Twitter

2:40 Labiotech.eu news4:58 SOTIO Biotech13:43 Eversana19:37 Carl Borrebaeck36:42 Concarlo TherapeuticsThis week, we have four interviews: Franjo Hanzl, vice president commercial development Europe at Eversana; Stacy Blain, founder and CEO of Concarlo Therapeutics; Jens Hennecke, chief business officer at SOTIO Biotech; and Carl Borrebaeck, chairman of the board of directors of Immunovia and professor at the Department of Immunotechnology at the University of Lund in Sweden.Concarlo TherapeuticsConcarlo Therapeutics is a U.S.-based preclinical-stage precision-medicine oncology company. It is developing a novel therapy for drug-resistant metastatic breast cancer as a first indication.Concarlo's patented IpY, a novel therapeutic peptide, will be the first to hit two targets, both CDK4/6- driven cell proliferation and CDK2-driven drug resistance at the same time, and the first to target p27. It is a specific cellular pathway to kill cancer cells rather than just slowing their proliferation.The novel approach relies on the role of p27Kpi, a natural inhibitor, an  "on-off" switch that regulates the activities of the major cancer-related proteins, CDK6, CDK4, and CDK2. EversanaEversana is a provider of global services to the life sciences industry. Its integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including start-ups and established pharmaceutical companies, to advance life sciences solutions.Labiotech spoke with Franjo Hanzl, vice president commercial development Europe, at the Medicon Valley Alliance annual summit in Copenhagen, Denmark.Medicon VillageDuring NLS Days, Labiotech visited Medicon Village, in Lund, Sweden. While there, we had the opportunity to chat with Carl Borrebaeck. To say he's involved in biotech would be an understatement. He is chairman of the board of directors of Immunovia and professor at the Department of Immunotechnology at the University of Lund in Sweden, as well as being director of Create Health. Borrebaeck, former vice president of the University of Lund, has been involved in many companies throughout his career, including Alligator Bio, SenzaGen and PainDrainer. He received the AKZONobel Science Award 2009, for contributions to cancer proteomics and antibody-based therapy, a Research! Sweden Award 2012 for his medical research of value for patients and health organizations, and the Royal Academy of Engineering Sciences Gold Medal 2012 for outstanding contributions to biomedical science. He was honored as the Biotech Builder of the Year in 2017.SOTIO BiotechSOTIO Biotech is a clinical stage immuno-oncology company owned by PPF Group based in Prague, Czechia. The company is building a pipeline of oncology programs by pursuing promising early-stage candidates through strategic licensing, M&A and in-house discovery efforts. SOTIO has been active in the clinic in 2022. The company initiated two clinical trials, the first was a phase 2 study for its lead IL-15 superagonist, SOT101. The initiation of the AURELIO-04 trial comes on the heels of positive phase 1/1b data, which showed 15 of 19 patients with advanced/metastatic solid tumors demonstrated clinical benefit with SOT101 in combination with pembrolizumab. The company also plans to enter the CAR-T space with the initiation of its BOXR trial in Q4 2022.  SOTIO is well funded into 2023 and plans to use those funds for posting more data across its already promising programs.We spoke with SOTIO Biotech at BIO-Europe.  

In this episode of AI For Pharma Growth, Dr Andree Bates is joined by Alan Crowther who leads the Navlin practice at the company Eversana.     Eversana's integrated platform combines data and artificial intelligence powered insights to answer pricing and access questions.    In this episode, Alan explains how to use artificial intelligence to make sure that you get your drug price right from the beginning. Pricing is one of the most difficult parts to get right for a launch and artificial intelligence might be able to help improve your company's launch price and get better results.   In this episode you will learn:  What Eversana is  How Navlin helps to improve pricing decisions What data Navlin uses to make pricing decisions How does AI differ from the traditional pricing approach   Click to connect with Dr. Andree Bates for more information in this episode: https://eularis.com/   Click for more information and for resources mentioned in this episode:  data.navlin.com   AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business.    This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.   As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses  her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.    This podcast features many experts who have developed powerful AI-powered tools that are the secret behind some time-saving and supercharged revenue-generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more.   Resources:  Dr. Andree Bates LinkedIn | Facebook | Twitter 

A first-time pharma launch sounds exciting......but it's demanding. Not everybody can handle it. Want to learn how to succeed? In this episode of Pharma Launch Secrets, Bozidar is joined by Rohit Sood, Executive Vice President at EVERSANA

A first-time pharma launch sounds exciting......but it's demanding. Not everybody can handle it. Want to learn how to succeed? In this episode of Pharma Launch Secrets, Bozidar is joined by Rohit Sood, Executive Vice President at EVERSANA

Michael Leis is an end-to-end marketer who has developed a portfolio of leadership experiences across healthcare, CPG, QSR, e-commerce, and software design. In each, his pride is in building dynamic teams designing record-breaking success for the world's largest, most complex brands. As Chief Content Strategy Officer at Publicis Health, Michael created and scaled the content marketing model across strategy, creative, production, systems, and distribution for 16 business units in the network. His blend of technology, media, behavior design and story structure has reoriented top healthcare brands to create stories worth sharing. Recently featured as having authored a global strategic best practice by WARC (2020) and Cannes Lions keynote presentation (2021), Michael architects teams to achieve unparalleled success, including the first-ever healthcare brand to win a platform-wide Shorty Award. Before joining Digitas Health, Michael led the creation and operation of the digital and social media practice at Draftfcb in Chicago. This included healthcare brands Stelara and Janssen's Positively Together HIV community. He also led brands across industries to new growth, including: Taco Bell, Sharpie, Cox Communications, KFC, Discover Financial, Tombstone Pizza, and Diners Club. Michael graduated Temple University with a degree in television screenwriting and production. He lives in the Philadelphia area with his wife, Jessica, and two sons, Jacob, and Maxwell. You'll find him at small venue music shows and sitting close enough at sports events that players can hear him.

In this episode of Pharma Launch Secrets, Bozidar is joined by Scott Snyder, Chief Digital Officer at EVERSANA.

In this episode of Pharma Launch Secrets, Bozidar is joined by Scott Snyder, Chief Digital Officer at EVERSANA.

Dave is joined by Fred Skinner, the CHRO at EVERSANA, for this episode of The Hennessy Report. He is also joined by Chad Brantner, a Keystone colleague and childhood friend of Fred from the small town of Sycamore, Illinois. Fred describes the "ridiculously awesome" culture at EVERSANA and their mission to revolutionize the pharmaceutical industry for both patients and providers. With 8,000+ employees, Fred says they've "cracked the code" on how to maintain culture while remaining inquisitive by leading with trust. He credits CEO Jim Lang for understanding the weight culture holds on a company and supporting HR initiatives. Listen now!

On this episode, we are joined by Mike DeLuca, Senior Vice President of Medical Affairs at EVERSANA. Mike brings more than twenty years of expertise to the table, as he candidly shares skills and strategies to help PharmDs identify the right industry role. Having started his career in retail pharmacy, Mike quickly rose to pharmacy manager, before deciding to pursue his MBA at Seton Hall, where he focused on pharmacy management and operations. Since then, Mike's extensive resume highlights his expertise and wide range of knowledge in many fields, including medical information, strategic marketing, regulatory and safety; as well as his experience building and developing strong teams. Tune in for career advice from a seasoned professional who knows what it takes to succeed in industry.

A big part of the reason my latest podcast guest, Rohit Sood, has become a successful and recognized leader, mentor and growth advisor in the pharma industry, is because he has been able to build successful teams. This is how his colleagues describe his unique success story as a recognized pharmaceutical industry scholar, Rutgers Business School lecturer, expert in organizational change, investor, and senior executive in life sciences who currently serves as Executive Vice President of Global Commercialization at EVERSANA. Rohit prefers to make deep and deliberate connections in business and he shares some truly unique, practical case studies and solutions on performance metrics, hiring, team dynamics, mentorship, growth mindset, and execution in this episode. 3:10 - Q: What were some of the strongest teams you worked with or led in your career that you still remember today? 6:47 - Q: What are the principles to building a strong team? 9:32 - Q: How do you design a structure around a team with a strong culture and vision? 13:45 - Q: Why do teams with best products and best performers fail? 19:27 – We discuss a story of a state tennis champion three years back to back who plays on a high school basketball team as a bench player the entire season, wins a state championship, and later admits openly to his teammates that winning as a bench player was his biggest accomplishment to date because he was a member of a team even though he had won individual tennis state championships. Rohit: we all have certain role players on our teams. You do not have to be at the center of every play or decision of your team. One of my favorite interview questions - tell me about a time when you were a role player - what was your contribution to the success of failure, and reason? 21:12 - Q: Performance metrics - Do you think performance metrics can be designed to promote collaboration as well as healthy competition? The Net Promoter Scores at Eversana are very high. Team Collaboration will be one of our metrics we will be tracking at Eversana that will be a part of the variable compensation of our employees! We will capture these metrics by gathering feedback from various brand teams across different functions. Did you feel included? Did you know what decisions were being made? We have also implemented frameworks around processes and operations. Our philosophy is that leaders have to be consistent. And consistency does not just happen. There have to be operations and processes in place that allow for consistency in execution. In summary, we are focused on 3 KPIs - 1) internal behaviors that ensure a collaborative culture; 2) behaviors that stimulate our clients and stakeholders' satisfaction of the quality of our products through their feedback; and 3) operations and processes to ensure consistency. 25:56 - Metrics also impact how you think about your goals for the year. We have three tiers of goals at Eversana. The first goals are tied to organizational performance. The second are corporate citizenship goals - make sure to do something in your role that impacts work outside of your day job! The third level of performance goals are related to individual interests. 33:06 - Aspirational idea of 1 single global metric - earnings per share. If not met, individual metrics come into play - hierarchy / tiered approach. 36:45 - Q: How do you recalibrate teams after successes or failures? 38:39 - Case study of a recent team member's problem with a deadline 41:28 – Q: Do you think the sense of belonging is what helps the best teams to succeed specifically? 45:24 - Q: How do you manage transitioning from team to team as often as we do today? 49:43 - Q: Should everyone start a team of their own regardless of their role or experience? 58:54 - Key Final Messages from Rohit!

Amy Parker is the Executive Design Director at Woods Creative. Amy runs Woods' Portland, Maine studio where she leads creative strategy, ideation, and digital design to make communication solutions, digital products, and visual languages for brands. Amy works in tandem with her research partner, Chris Bransfield, to conduct primary one-on-one interviews for design and Human Experience/User Experience research to gain insight, understand nuanced problems, ask questions, and uncover findings to identify form, content and functional needs. Amy's current clients hire her for her design work, insights into how visual design elevates products for the people using them, and energetic approach towards solving challenging business problems with design.   A few notable clients Amy has worked with are; Pegasystems, Daily Table, EVERSANA, University of St. Gallen, 240 Strings, John Hancock, SPACE Gallery, Material Wise (Podcast), Bank of America, Noble Biomaterials, Cessna, New Balance, Puma, and Rising Bear Foods.   Amy holds a BFA from the New England School of Art and Design at Suffolk and serves on the board of directors with AIGA Boston. Amy Parker's Instagram: https://www.instagram.com/amyparkerdesign/ Wood's Creative Instagram: https://www.instagram.com/woodscreative/ Wood's Creative Website: http://www.woodscreative.co/   Pixel Perfect's Instagram: https://www.instagram.com/pixelperfecttalk/ Pixel Perfect's Website: https://www.pixelperfect.blog/  

Marie E. Lamont, President and Chief Operating Officer at Inteliquet™, a leader in clinical trial matching, discusses the impact COVID has had on clinical trials and how companies have leveraged advanced technology tools to further research, improve patient recruitment, and use AI and Machine Learning to recognize behaviors and patterns to constantly improve on the data collection process overall. Marie E. Lamont is responsible for the overall vision and operations of Inteliquet. With the goal of providing patients and physicians access to the latest and best treatment options and care available, she helps commercialize Inteliquet's offerings of intelligent technology, insights, and services to improve the clinical trial process, research, and translational medicine. With more than 25 years as a global biotech leader, Marie has significant commercial and operational expertise. She has held senior leadership positions in many areas focusing on corporate strategic planning and analytics, commercial operations, finance and accounting, patient services, and payer contracting and reimbursement. Prior to Inteliquet, Marie headed up an executive consulting and advisory firm for the life science and technology industries that advised companies on commercialization and integration planning, M&A support, and global market expansion. Before her consultancy, Marie was President of the Patient Services Business at Dohmen Life Science Services (DLSS), which was subsequently sold and is now part of EVERSANA (a provider of global services to the life science industry). She directed all aspects of the unit and was responsible for improving the client and patient focus by shoring up the underlying infrastructure, as well as improving patient support and employee engagement. She also was heavily involved in the success of DLSS's brand positioning, strategic road mapping, sales business development, and patient journey adoption, along with targeting analytics for key initiatives. Prior to DLSS, Marie was Global Head of Business Strategy and Commercial Operations for Rare Disease at Sanofi Genzyme. She had stewardship for the $2.9B business where annual operating profit improved at a rate greater than revenue. As a member of the senior leadership team, she was tasked with decision analytics and support as well as bringing together disparate groups and functions into a cohesive, comprehensive global unit. While reestablishing a Rare Disease global strategy, she worked to align efforts with a range of functions, including R&D, Biologics Manufacturing, and Medical/Regulatory Affairs. She also helped to lead humanitarian programs that provided free therapy for more than 1,100 patients suffering from rare diseases in emerging markets. Prior to this position, she held several senior operational and finance roles. She took on the assignment of Vice President of Integration for Finance and Accounting following the Sanofi acquisition. Before this assignment, she was Vice President of Operations & Finance for the International Group where the business grew from $100M in 2002 to $2B at time of the Sanofi acquisition. She guided the operational strategy for the international infrastructure on a regional and country basis for the Oncology, Transplant, Renal, Biosurgery, and Rare Disease Business Units. Before this role, she directed Corporate Financial Planning & Analysis and Strategic Planning. Marie holds a bachelor's degree in Business from Saint Michael's College, and attended Harvard Business School and Kellogg Executive Education programs. She lives in the St. Louis area. #COVID19

In this episode, I speak with Ed Cox, who is an Executive Vice President of Strategic Alliances and Global Head of Digital Medicines at EVERSANA. In our conversation, we focus on his journey through Dthera and the many lessons learned.  But before we dive in: Those of you who know Ed, will agree, he is a memorable guy, and therefore I am super surprised I can not even remember where we first met but what I do know is that every time I speak with Ed, I feel like I have known him my whole life.   >>Click here to read the transcript Be sure to check out my previous episode where I spoke with David Klein, CEO and Founder of Click Therapeutics - a company that was started in 2012 as a smoking cessation app and now with a pipeline of DTx therapies and a $500M deal with Boehringer Ingelheim.  Guest Links and Resources: Connect with Edward Cox: LinkedIn Visit EVERSANA : Twitter | LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Sam is a CEO coach, interim CEO/CTO/CFO, a Silicon Valley advisor and the author of 21 Secrets of Successful Startups, a book about world-class execution for startups. As a serial entrepreneur, he has been CEO, CTO, or VP Engineering / TechOps for five companies, driving multiple acquisitions. As a hands-on “roll up the sleeves” startup advisor, Sam draws from his 30+ years of successes and failures to train and help entrepreneurs with execution, fundability, fundraising, strategy, product/market fit, product management, finance, operations, legal, talent development and founder wellness.     Elnaz Sarraf, who is a serial entrepreneur with over 15 years of experience in technology, business, sales, and marketing. She is currently the CEO and Founder of ROYBI; an investor backed EdTech company focusing on early childhood education, that recently raised $4.2 million in its seed round. Before starting ROYBI, Elnaz co-founded and led a consumer electronics/IoT company, iBaby, serving as the company's President.  As an immigrant and female founder, Elnaz has made worthy accomplishments in a short duration living in the US. Honors include being selected as Nasdaq Entrepreneurial Center Milestone Maker 2018, named the Woman of Influence through Silicon Valley Business Journal in 2016 and Entrepreneur of The Year in 2016 in Silicon Valley. She has been a speaker at several conferences such as the Mobile World Congress, ASU GSV Summit, Consumer Technology Association, and more.      Sandra Shpilberg is the Founder and CEO of Adnexi, a disease intelligence platform for the next generation of biopharma treatments. Prior to this, Sandra was the Founder and CEO of Seeker Health, a breakthrough digital patient finding platform, which accelerates drug development and commercialization for biopharmaceutical companies. Seeker Health was acquired by EVERSANA in September 2018. She's the author of New Startup Mindset, a book on her non-traditional founder's journey and lessons learned starting, building and exiting this company. She's a featured contributor at Thrive Global, InsightTimer and Hackernoon.   Daniel Edwards is currently the CEO and Chairman of Transactive, a international financial technology company that provides payment infrastructure software and payment services globally.  Under Daniel's leadership Transactive has successfully launched its software, services over thousand customers, done over $1bn in payments and achieved profitability.  Previously Daniel was the Vice President of Finance and Operations at Mobile Gaming Technologies. Mobile Gaming Technologies was the world's first crypto iGaming platform. Under his leadership Mobile Gaming Technologies became venture backed, scaled international and achieved profitability. He also lead Mobile Gaming Technologies through several successful capital raises, raising over $40m for the company.  MGT became the first blockchain company in the world to sponsor a major league sports team, Arsenal Football Club from London. Eventually the MGT sold the company to Novomatic, the largest privately held gaming company in the world with over 5bn in revenue per year.  Prior to joining Mobile Gaming Technologies, Daniel worked as an Investment Banker at Financial Technology Partners, D.A. Davidson and Wells Fargo / Wachovia. He advised technology companies on mergers and acquisitions, capital raising and strategic corporate development. He has successfully closed over 15 M&A and capital raise transactions. Daniel is also a board member of several technology companies spanning from London to Silicon Valley. He is a financial technology enthusiast and speaks at conferences all around the world about financial technology, blockchain and cryptocurrency. Daniel graduated with a B.S. in Finance & minor in Chemistry from Oregon State University. 

Sandra Shpilberg is the Founder and CEO of Adnexi, a disease intelligence platform for the next generation of biopharma treatments. Prior to this, Sandra was the Founder and CEO of Seeker Health, a breakthrough digital patient finding platform, which accelerates drug development and commercialization for biopharmaceutical companies. Seeker Health was acquired by EVERSANA in September 2018. She's the author of New Startup Mindset, a book on her non-traditional founder's journey and lessons learned starting, building and exiting this company. She's a featured contributor at Thrive Global, InsightTimer and Hackernoon. On today Show we Talk about What question should a founder or founder team should ask themselves about a company before starting it? How important is positioning one's company? The temptation to take venture funding and the positives and the negatives of going down that path?   Connect with Sandra Shpilberg adnexi.com sandrashpilberg.com  Linkedin https://www.linkedin.com/in/sandra-shpilberg-b7b334/ Website https://www.sandrashpilberg.com/       CONNECT WITH SHAWN https://linktr.ee/ShawnflynnSV Shawn Flynn's LinkedInAccount Silicon Valley LinkedInGroup Account Shawn Flynn's FacebookAccount Email Shawn@thesiliconvalleypodcast.com